Gelesis Holdings Inc
Change company Symbol lookup
Select an option...
GLS Gelesis Holdings Inc
CSTL Castle Biosciences Inc
GIC Global Industrial Co
EQHA EQ Health Acquisition Corp
DLCAW Deep Lake Capital Acquisition Equity Warrant Exp 04 Jan 2026 *W EXP 01/04/2026
CDK CDK Global Inc
CNC Centene Corp
ONXXF Ontex Group NV
INDB Independent Bank Corp (Massachusetts)
IIII Insu Acquisition Corp III
Go

Company profile

Gelesis Holdings, Inc., formerly Capstar Special Purpose Acquisition Corp., is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of FC.

Closing Price
$4.97
Day's Change
0.04 (0.81%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.09
Day's Low
4.86
Volume
(Below Average)
Volume:
66,776

10-day average volume:
80,851
66,776

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.